SBIO
ALPS Medical Breakthroughs ETF
ALPS Medical Breakthroughs ETF is an exchange-traded fund incorporated in the USA. The ETF seeks investment results that correspond generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs Index (ticker symbol: PMBI).
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 161.7 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Dec 30, 2014 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| KYMERA THERAPEUTICS, INC. | 4.3 % |
| CELCUITY INC. | 4.1 % |
| ALKERMES PLC | 4.0 % |
| MIRUM PHARMACEUTICALS, INC. | 4.0 % |
| SPYRE THERAPEUTICS INC | 3.8 % |
| CG ONCOLOGY, INC. | 3.7 % |
| APOGEE THERAPEUTICS, INC. | 2.9 % |
| XENON PHARMACEUTICALS, INC. | 2.9 % |
| NEWAMSTERDAM PHARMA CO NV | 2.6 % |
| TRAVERE THERAPEUTICS, INC. | 2.5 % |
Constituent Breakdown
| Number of holdings | 75 |
| Herfindahl-Hirschman Index | 215 |
| Wgt avg mkt cap (mns) | $2,223 |
| Large cap (>$10bn) | 48.8% |
| Mid cap ($2-10bn) | 35.9% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 89.9% |
| Emerging mkts. | 1.5% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 81.5 % |
 |
IRELAND | 4.1 % |
 |
CHINA | 1.5 % |
 |
BELGIUM | 1.2 % |
 |
GERMANY | 0.9 % |
 |
BRITAIN | 0.9 % |
 |
SWITZERLAND | 0.8 % |
 |
CAYMAN ISLANDS | 0.5 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 6.3% | 86.9% | 27.2% | 19.9% | 3.2% | 7.9% | -- | 7.1% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.5% | -- | 0.5% |
| Total Returns | 6.3% | 86.9% | 27.2% | 20.0% | 3.2% | 8.4% | -- | 7.6% | Ann. Volatility | 32.6% | 29.1% | 31.4% | 30.3% | 33.6% | 33.2% | -- | 34.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.22 | 24% |
| MSCI EAFE | 0.96 | 24% |
| MSCI Emg Mkts | 0.62 | 18% |
Liquidity Measures
| Avg. volume (000) | 22 |
| ADV traded (mns) | $1 |
| Turnover | 0.7% |
| Avg. Bid/Ask (% of price) | 0.37% |
Technical Indicators
| 30d moving avg. (EMA) | $53.90 |
| Relative strength (RSI) | 53 |
| MACD/Signal | -0.09/-0.08 |
| Bollinger Bands (Upper/Lower) | $56.93/$51.48 |
| Short interest (% of AUM) | 1.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. SBIO |
Expenses vs. SBIO |
ALTAR Score™ vs. SBIO |
|---|---|---|---|---|
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 29.4% | +29 bp | 0.0% |
| XBI | State Street SPDR S&P Biotech ETF | 27.6% | -15 bp | -0.1% |
| IBRN | iShares Neuroscience and Healthcare ETF | 17.9% | -3 bp | 0.0% |
| BBP | Virtus LifeSci Biotech Products ETF | 17.1% | +29 bp | -3.8% |
| CANC | Tema Oncology ETF | 15.3% | +25 bp | -2.0% |
| LFSC | F/m Emerald Life Sciences Innovation ETF | 14.5% | +29 bp | 0.0% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 10.8% | -15 bp | -0.9% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 10.8% | +10 bp | -1.2% |
| FMED | Fidelity Disruptive Medicine ETF | 10.6% | 0 bp | -1.2% |
Risk and Returns: SBIO vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/30/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.0%
ALTAR SCORE™
PERCENTILE
AVOID
ETFRC RATING
There are 1,400 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. SBIO's ALTAR Score™ is approximately 0.0 standard
deviations above the category average. This places SBIO in the percentile
among funds in the category.
Sell-Side Consensus
$70.68
PRICE TARGET
+29.8%
UPSIDE